Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Decensi

Showing results (11-20 of 91) with videos related to

Pageof 10
Sort By:
Journal of Cellular Biochemistry. Supplement|January 1, 1993
Breast cancer chemoprevention: studies with 4-HPR alone and in combination with tamoxifen using circulating growth factors as potential surrogate endpointsA Decensi, F Formelli, R Torrisi, et al.
Annals of the New York Academy of Sciences|January 25, 2002
The Italian breast cancer prevention trial with tamoxifen: findings and new perspectivesA Guerrieri-Gonzaga, A Galli, N Rotmensz, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Pilot study of high dose fenretinide and vitamin A supplementation in bladder cancerA Decensi, S Bruno, R Torrisi, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1995
The metabolite N-4-methoxyphenylretinamide is a major determinant of fenretinide induced decline of plasma insulin-like growth factor-1R Torrisi, F Pensa, V Fontana, et al.
Oncology Reports|May 25, 2011
Fenretinide in breast-cancer chemoprevention (review)A Decensi, F Formelli, R Torrisi, et al.
IARC Scientific Publications|January 1, 1996
Chemoprevention of breast cancer with fenretinideU Veronesi, G De Palo, A Costa, et al.
Drugs|July 4, 2001
Chemoprevention of breast cancer with fenretinideR Torrisi, A Decensi, F Formelli, et al.
Tumori|April 30, 1992
Phase II study with lonidamine in the treatment of hormone-refractory prostatic cancer patientsF Boccardo, D Guarneri, M Pace, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1988
Estramustine phosphate (estracyt) following androgens in men with refractory stage D2 prostate cancerF Boccardo, A Decensi, D Guarneri, et al.
The Prostate|January 1, 1994
Effect of the nonsteroidal antiandrogen nilutamide on adrenal androgen secretionA Decensi, R Torrisi, P Marroni, et al.
Pageof 10

Showing results (11-20 of 91) with videos related to

Sort By:
Pageof 10
Journal of Cellular Biochemistry. Supplement|January 1, 1993
Breast cancer chemoprevention: studies with 4-HPR alone and in combination with tamoxifen using circulating growth factors as potential surrogate endpointsA Decensi, F Formelli, R Torrisi, et al.
Annals of the New York Academy of Sciences|January 25, 2002
The Italian breast cancer prevention trial with tamoxifen: findings and new perspectivesA Guerrieri-Gonzaga, A Galli, N Rotmensz, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Pilot study of high dose fenretinide and vitamin A supplementation in bladder cancerA Decensi, S Bruno, R Torrisi, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1995
The metabolite N-4-methoxyphenylretinamide is a major determinant of fenretinide induced decline of plasma insulin-like growth factor-1R Torrisi, F Pensa, V Fontana, et al.
Oncology Reports|May 25, 2011
Fenretinide in breast-cancer chemoprevention (review)A Decensi, F Formelli, R Torrisi, et al.
IARC Scientific Publications|January 1, 1996
Chemoprevention of breast cancer with fenretinideU Veronesi, G De Palo, A Costa, et al.
Drugs|July 4, 2001
Chemoprevention of breast cancer with fenretinideR Torrisi, A Decensi, F Formelli, et al.
Tumori|April 30, 1992
Phase II study with lonidamine in the treatment of hormone-refractory prostatic cancer patientsF Boccardo, D Guarneri, M Pace, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1988
Estramustine phosphate (estracyt) following androgens in men with refractory stage D2 prostate cancerF Boccardo, A Decensi, D Guarneri, et al.
The Prostate|January 1, 1994
Effect of the nonsteroidal antiandrogen nilutamide on adrenal androgen secretionA Decensi, R Torrisi, P Marroni, et al.
Pageof 10